Compare Adaptive Biotechnologies Corp (ADPT) vs Arqit Quantum Inc (ARQQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Arqit Quantum Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.9 (market cap $3.33B), while Arqit Quantum Inc trades at $19.6 (market cap $345.44M). The key difference: Adaptive Biotechnologies Corp is far larger — about 9.6× Arqit Quantum Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | ARQQ | |
|---|---|---|
Market Cap | $3.33B | $345.44M |
Sector | Health | Technology |
52-Week High | $22.37 | $58.27 |
52-Week Low | $10.24 | $11.78 |
Enterprise Value | $3.19B | $318.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ARQQ trades at $22.13, down 5.89% today, with a bullish technical signal supported by moving averages. The company reported $530K revenue for 2025 but significant losses of -$35.34M net income, with negative margins and high P/S ratio of 319.93. Recent news highlights quantum security contract wins and 829% YoY revenue growth in H1 FY26, suggesting potential turnaround momentum despite current financial challenges.
Outlook remains speculative with high execution risk; substantial revenue growth and government/telecom deals offer upside, but persistent losses and negative ROE (-181%) pose significant shareholder value concerns. Analyst consensus is divided with 50% buy rating, indicating cautious optimism amid financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →
